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ARTICLE
Plasmodium vivax chloroquine resistance links
to pvcrt transcription in a genetic cross
Juliana M. Sá1, Sarah R. Kaslow 1, Roberto R. Moraes Barros1, Nicholas F. Brazeau2, Christian M. Parobek3,
Dingyin Tao 4, Rebecca E. Salzman1, Tyler J. Gibson 1, Soundarapandian Velmurugan5, Michael A. Krause1,
Viviana Melendez-Muniz1, Whitney A. Kite1, Paul K. Han1, Richard T. Eastman 1, Adam Kim6, Evan G. Kessler1,
Yonas Abebe5, Eric R. James5, Sumana Chakravarty5, Sachy Orr-Gonzalez7, Lynn E. Lambert7, Theresa Engels8,
Marvin L. Thomas8, Pius S. Fasinu9, David Serre 6, Robert W. Gwadz1, Larry Walker 9, Derrick K. DeConti10,
Jianbing Mu1, Jeffrey A. Bailey 9,11, B. Kim Lee Sim5, Stephen L. Hoffman5, Michael P. Fay 12,
Rhoel R. Dinglasan4,13, Jonathan J. Juliano2,3,14 & Thomas E. Wellems 1
Mainstay treatment for Plasmodium vivax malaria has long relied on chloroquine (CQ) against
blood-stage parasites plus primaquine against dormant liver-stage forms (hypnozoites),
however drug resistance confronts this regimen and threatens malaria control programs.
Understanding the basis of P. vivax chloroquine resistance (CQR) will inform drug discovery
and malaria control. Here we investigate the genetics of P. vivax CQR by a cross of parasites
differing in drug response. Gametocytogenesis, mosquito infection, and progeny production
are performed with mixed parasite populations in nonhuman primates, as methods for P.
vivax cloning and in vitro cultivation remain unavailable. Linkage mapping of progeny sur-
viving >15 mg/kg CQ identifies a 76 kb region in chromosome 1 including pvcrt, an ortholog of
the Plasmodium falciparum CQR transporter gene. Transcriptional analysis supports upregu-
lated pvcrt expression as a mechanism of CQR.
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Malaria cases from Plasmodium vivax infection numberan estimated 14.3 million annually and are often lifethreatening1. Mainstay treatment for more than half a
century has been chloroquine (CQ) for blood-stage parasitemia
followed by primaquine to eradicate persistent liver-stage (hyp-
nozoite) infection2. Spreading drug resistance now confronts this
regimen and threatens malaria control programs, particularly in
Papua New Guinea and Indonesia where artemisinin-based
combination therapies are instead recommended3. Molecular
understanding of resistance will provide information in support
of malaria control and antimalarial drug discovery.
Features of CQR differ between P. vivax and Plasmodium
falciparum, the main agent of malaria morbidity and mortality in
Africa. CQ-resistant (CQ-R) P. falciparum strains spread through
Southeast Asia and South America in the 1960s, entering Africa
in the late 1970s and causing catastrophic resurgences of mor-
bidity and mortality4, whereas P. vivax CQR was not reported
until the late 1980s in Papua New Guinea5. P. falciparum CQR
results from mutations in the pfcrt (P. falciparum CQ resistance
transporter) gene, including a change in codon 76 that protects
the parasite against CQ accumulation and damage6,7. In contrast,
P. vivax CQR could not be attributed to codon mutations in pvcrt
(also termed pvcrt-o, pvcg10), the P. vivax ortholog of pfcrt, nei-
ther in a study of CQ treatment failures in humans and mon-
keys8, nor in recent genome wide association surveys9,10. These
findings left open the possibility that pvcrt expression levels have
a role in resistance.
Heterologous expression experiments have shown that pvcrt
introduced by transfection can affect CQ response in P. falci-
parum11 and alter CQ accumulation in Dictyostelium dis-
coideum11 and yeast12. Increased transcript levels of pvcrt and the
P. vivax multidrug resistance gene (pvmdr-1) have been reported
in samples from patients with severe P. vivax malaria13 or who
suffered CQ treatment failures14. In contrast, another study found
that pvcrt transcription was related to parasite stage but not to
ex vivo CQ susceptibility in patient samples15. The lack of
practical methods to routinely cultivate, isolate clones, and
genetically manipulate parasites in the laboratory continues to
limit direct studies of the CQR mechanism in P. vivax. Experi-
mental investigations have consequently relied on nonhuman
primates (NHP), such as Aotus or Saimiri New World monkeys,
and a limited number of P. vivax lines adapted to these models.
Here we report the production and analysis of a genetic cross of
P. vivax parasites having different CQ response phenotypes. Our
findings identify upregulated expression of the pvcrt gene as a
mechanism of drug resistance.
Results
Design of a P. vivax laboratory genetic cross. Our experiments
initially explored the use of sporozoites from infected Anopheles
mosquitoes to inoculate Aotus nancymaae or Saimiri boliviensis
monkeys, but multiple attempts failed to produce adequate pro-
geny infections. These attempts included ten different monkey-
adapted P. vivax lines (NIH-1993, Vietnam-IV, AMRU-I, Indo-
nesia-XIX, Indonesia-I/CDC, Brazil-I/CDC, Salvador-II, North
Korea, Panama, and Chesson) by blood feedings to ca. 15,000
mosquitoes of available species: Anopheles dirus (South East
Asia), Anopheles albimanus (Central America), Anopheles ste-
phensi (India), Anopheles freeborni (North America), and Ano-
pheles gambiae (Africa). Some parasite lines did not infect the
mosquitoes (through direct or membrane feeding) despite
observation of healthy-appearing gametocytes; other lines infec-
ted mosquitoes and yielded sporozoites but failed to produce
blood-stage infections after inoculation of the sporozoites into the
monkeys. We therefore turned to a splenectomized chimpanzee
as host for the cross. This strategy depended upon two separate
inoculations of the individual animal: (i) a joint inoculation of
parental P. vivax blood-stage parasites to produce infective male
and female gametocytes for cross-fertilization in Anopheles
mosquitoes; and (ii) subsequent inoculation of cryopreserved
sporozoites, to infect the liver with a variety of progeny that
subsequently enter the chimpanzee bloodstream (Fig. 1a).
CQ selection of distinct gametocyte subpopulations. Two P.
vivax lines were chosen as candidate parents for inoculation of
the chimpanzee: CQ-R AMRU-I that survives a total of 30 mg/kg
CQ in Aotus16, and NIH-1993, closely related to, but genetically
distinct from, the Salvador-I line (Supplementary Table 1), which
typically does not survive this treatment dose in Aotus17 (Sup-
plementary Fig. 1, Supplementary Table 2; recommended CQ
treatment for adult humans is 25 mg/kg total dose delivered orally
over 3 days2). NIH-1993 and AMRU-I-parasitized erythrocytes
were obtained from individual infections of Aotus monkeys,
sterilely washed, resuspended, and inoculated into the chimpan-
zee as a mixture of 5 × 106 blood-stage parasites from each line.
Thirteen days post blood inoculation (DPBI), asexual parasites
and gametocytes were observed in thin blood smears (Supple-
mentary Fig. 2a, Supplementary Table 3), but polymerase chain
reaction (PCR) assays 18 DPBI detected only microsatellite alleles
of the NIH-1993 line (Supplementary Fig. 2b). Therefore, 21
DPBI, the chimpanzee was given a sub-therapeutic single dose of
CQ (2.7 mg/kg) to increase the representation of any CQ-R
parasites. This uncovered no AMRU-I parasites, indicating that
the AMRU-I line had failed to adapt and multiply in the chim-
panzee; however, the CQ dose increased the representation of an
NIH-1993 subpopulation distinguishable from the major CQ-
sensitive (CQ-S) subpopulation by a variety of microsatellite
markers (Supplementary Table 4). These subpopulations, identi-
fied as NIH-1993-S and NIH-1993-R, were present in comparable
numbers 28 and 31 DPBI and therefore served as parents of the
genetic cross.
Generation of NIH-1993 S × R recombinant sporozoites. A.
stephensi, A. freeborni, A. gambiae, and A. dirus mosquitoes were
infected on six occasions with the mixed NIH-1993-S and NIH-
1993-R gametocytes, both by direct feeding on the chimpanzee
and by laboratory feedings of blood samples through membranes,
to produce recombinant sporozoites (Supplementary Fig. 2,
Supplementary Table 5; Feeds 1–6). Single oocysts from mosquito
midguts presenting both alleles of distinguishing parental mar-
kers suggested cross-fertilization of NIH-1993-S and NIH-1993-R
gametes from feeds after the 2.7 mg/kg CQ dose (Supplementary
Fig. 2c; Feeds 3–6). Further, either of two types of circumspor-
ozoite protein (CSP) VK210 or VK247 were found in the spor-
ozoites from mosquito salivary glands (Fig. 1b, c), indicating
inheritance of distinct alleles from the parents. Samples of asep-
tically isolated sporozoites were cryopreserved and confirmed to
be infective in hepatocyte invasion assays18 (Supplementary
Table 5). The chimpanzee was cured 34 DPBI with Malarone
(confirmed by follow-up PCR).
Development of NIH-1993 S × R recombinant blood stage
progeny. Six months after cure, the chimpanzee was intrave-
nously inoculated with the NIH-1993-S × NIH-1993-R spor-
ozoites from Feeds 4 and 5. NIH-1993 S × R blood-stage progeny
from this cross were microscopically detected 8 days post spor-
ozoite inoculation (DPSI; Supplementary Table 6). Blood was
collected 15 and 18 DPSI (Progeny Pools 1 and 2), and the
chimpanzee was treated with CQ 5mg/kg/day × 3 days. Blood-
stream parasitemia declined to levels detected only by PCR, then
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increased to 0.01% in thin blood films 43 DPSI. After an addi-
tional 3-day CQ treatment of 2.5 mg/kg/day beginning 53 DPSI,
parasites were detectable by PCR until final cure at 102 DPSI with
Malarone plus primaquine; follow-up PCR testing confirmed no
remaining infection after one year.
NIH-1993 S × R progeny differ in CQ response. Samples of the
unselected mixed progeny were inoculated into 20 Aotus or Sai-
miri monkeys for drug response analysis (Supplementary Fig. 3).
Parasitemia developed in 17 of these monkeys. After CQ treat-
ment (15–55mg/kg total dose), 10/17 of these infections recru-
desced, in many cases after the parasitemias had decreased below
microscopically detectable levels (Supplementary Fig. 4,
Supplementary Table 7). HPLC-mass spectroscopy of plasma
samples from these monkeys confirmed therapeutic CQ levels
(≥10 ng/mL)2, with a single exception (Supplementary Table 8).
Linkage-group selection maps a chromosome 1 determinant.
Infected blood from each monkey before CQ administration
(NIH-1993 S × R unselected progeny) and after recrudescence
(selected progeny) provided 10 sample pairs for linkage group
selection analysis (LGS)19. Quantitative inheritance signals were
obtained from these LGS pairs by PCR with 37 polymorphic
microsatellite markers distributed irregularly across the 14 P.
vivax chromosomes (Supplementary Fig. 5). CQ selection E
values displayed by heat map (Fig. 2a, Supplementary Table 9),
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Fig. 1 Steps in the production of a P. vivax genetic cross and generation of recombinant progeny. aWork flow of the cross. Blood-stage parasites of P. vivax
parental lines were collected from Aotus monkeys and co-inoculated into a Pan troglodytes chimpanzee. After development of parasitemia, chimpanzee
blood samples containing infectious gametocytes were fed on multiple occasions to Anopheles mosquitoes to allow cross-fertilization of parental lines.
Recombinant sporozoites from mating events were recovered from the mosquitoes and cryopreserved, and the chimpanzee was treated to eliminate any
remaining P. vivax parental parasites. The recombinant sporozoites were inoculated into the chimpanzee 6 months after cure of parental lines infection to
recover mixed blood-stage progeny from the cross. Pools of recombinant progeny were collected and sub-inoculated into Aotus and Saimiri monkeys for
phenotypic characterization and genetic analysis. Solid arrows indicate the first chimpanzee infection inoculated with blood-stages from the parental lines,
and dotted arrows the second infection with recombinant progeny sporozoites. b Immunofluorescence assays were performed on recombinant sporozoites
with antibodies specific for the VK210 and VK247 versions of P. vivax CSP expressed by distinct parental lines. Sporozoites expressing P. vivax CSP VK210
type are represented in green and sporozoites expressing VK247 are represented in orange. Scale bar indicates ~25 µm. c Percentages of P. vivax
sporozoites expressing CSP VK210 and VK247 in the infected mosquitoes. Four batches of cryopreserved sporozoites were obtained from An. stephensi, An.
freeborni, An. dirus, and An. gambiae mosquitoes fed 18, 21, 28, 31, and 34 days after the co-inoculation (sporozoites from 18 and 21 feedings were combined
and presented in the first bar). The chimpanzee was treated with a low dose of CQ (2.7 mg/kg) on day 21 to increase CQ-R P. vivax parental population
carrying the VK247 marker and improve chances of cross-fertilization over self-mating events in the mosquito
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showed increases (E > 1), as well as decreases (E < 1) among the
LGS pairs for every marker except the two specific to chromo-
some 1: MS334 and a pvcrt intron 9 polymorphism (In9pvcrt),
which showed positive selection in all LGS pairs in the post-CQ
samples. MS334 is located ~1 kb upstream from the initiation
codon of pvcrt. This finding of strong linkage to the NIH-1993-R
phenotype is unlikely to be an artifact of redundant progeny
pools, as each LGS recrudescence showed a distinct pattern of E
values consistent with a unique mixed population of recombi-
nants (two-sided p= 0.026: under the null hypothesis that the
markers are independently inherited between chromosomes and
that their E-values are equally likely to be >1 or <1 without
selection).
A 76 kb region selected by CQ includes pvcrt. To delimit the
genomic region linked to CQR, we performed targeted genome
sequencing20,21 of chromosome 1 on DNA from six LGS pairs
before and after CQ treatment (DNA was insufficient from four
recrudescences detected only by PCR, despite use of whole gen-
ome amplification; Supplementary Fig. 4c, f, i, j). Using with-in
sample allele frequencies smoothed by a 40-SNP running median
sliding window in six monkey pairs (Supplementary Table 10), we
identified a well-demarcated 76 kb selection valley syntenic with
the region of P. falciparum chromosome 7 harboring the pfcrt
gene8 (Fig. 2b, Table 1). On chromosome 5, which contains a
microsatellite marker (MS15) with E values >1 in 8/10 recru-
descent infections, targeted genome sequencing detected no
region significantly selected by CQ (Supplementary Fig. 6;
insufficient DNA was available to complete similar sequencing of
the other chromosomes). We note that our search would not have
been able to map the presence of mutation that was the same in
both parents, nor does it dismiss the possibility that the 37
microsatellite markers could have missed the inheritance of
separate, additional determinant required for resistance.
Although the frequency of meiotic crossover events is not
reported for P. vivax, information is available from two other
Plasmodium species: P. falciparum and Plasmodium chabaudi
chabaudi, a rodent malaria parasite that is evolutionarily closer to
P. vivax than to P. falciparum22. Excluding the highly recombi-
nogenic subtelomeric regions, genome genetic lengths of 1655
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Fig. 2 Effect of CQ selection on mixed progeny populations from the NIH-1993-R × NIH-1993-S cross. a Heat map showing relative prevalences of
microsatellite polymorphisms among the mixed progeny populations before and after CQ selection in Aotus or Saimirimonkeys. Colored squares in the heat
map represent E values from microsatellite marker analysis of recrudescences in 10 monkeys (blue, E > 1; yellow, E < 1). Among the 14 P. vivax
chromosomes, only a region of chromosome 1 shows positive selection in all samples after drug pressure (microsatellites MS334 and In9pvcrt). Columns
with both blue and yellow squares indicate no consistent selection of any microsatellites in the other 13 chromosomes and are consistent with different
combinations of individual progenies in each monkey. b Linkage group selection analysis of chromosome 1 by targeted genome sequencing. Aggregate
smoothed log2-fold changes of pre-CQ and post-CQ treatment allele frequencies are plotted as dots; 95% CIs for individual points based on bootstrapping
with replacement, are indicated by the vertical lines. A bootstrap range that does not overlap with 0 suggests selection of the corresponding region with
CQ exposure
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and 1570 centiMorgans (cM) have been reported for P.
falciparum23,24, and 1676 cM for P. c. chabaudi25. Another esti-
mate of 2210 cM for P. falciparum did not distinguish the con-
tributions of markers from subtelomeric regions including gene
families involved in processes of antigenic variation26. For the
purposes of our present discussion, use of core genetic lengths are
appropriate for the 14 nuclear chromosomes, indicating 16.55,
15.70, and 16.76 crossovers per generation by definition of the
centiMorgan. These yield averages of 1.19, 1.12, and 1.20 cross-
over per chromosome, but individual numbers vary with chro-
mosome size23–25. We suggest that a particularly high level of
recombination activity would have been necessary in the vicinity
of a postulated second determinant for the markers to have
missed it outside of the chromosome region carrying pvcrt.
Differential pvcrt transcription associated with CQ response.
No non-synonymous changes of pvcrt were associated with CQR
in the cross, consistent with previous findings8. To evaluate the
possibility that changes in pvcrt expression confer CQR, we tested
mRNA samples from five LGS pairs by quantitative reverse
transcription-PCR (qRT-PCR). These experiments included eight
samples of CQ-selected mixed progeny from the five LGS pairs.
Results demonstrated greater pvcrt mRNA transcript levels in
the CQ-selected mixed progeny (Fig. 3a, Supplementary Table 11;
2-ΔΔCt ratio (CQ-selected/unselected)= 2.40 (95% CI: 1.53, 3.77;
p= 0.006).
PvCRT protein quantitation can be difficult as it is a food
vacuole membrane protein and material from blood samples or
isolates under short-term ex vivo conditions is very limited. We
therefore turned to targeted liquid chromatography multiple
reaction monitoring with a heavy labeled (C13) isotopic peptide
internal standard (LC–MRM–MS)27 for its ability to quantify low
abundance proteins from limited biological samples28. By this
method, signals from three transitions were obtained from a
peptide of PvCRT (Supplementary Table 12). Eighteen samples
were obtained from 15 P. vivax-infected monkeys: four infected
with mixed NIH-1993 S × R unselected progeny, four with CQ-
selected mixed progeny, three with Chesson29 CQ-S parasites,
and two each with the CQ-R AMRU-I and Indonesia-XIX30 lines.
Parasite-infected red blood cells (pRBCs) were purified by a
magnetic column and analyzed by LC–MRM–MS for total
PvCRT content (Supplementary Tables 13 and 14). Calculations
of cellular PvCRT content from these results yielded geometric
means of 1.32 (95%CI, 0.45–3.91) and 2.62 (95%CI, 0.88–7.75)
zeptomoles per pRBC in the unselected and selected NIH-1993
S × R progeny, respectively (Fig. 3b; two-sided Welch’s t-test p=
0.23, geometric mean ratio 1.98, 95% CI: 0.58, 6.75). Wide
confidence intervals of these estimates reflect the difficulties of
both low-level membrane protein measurements and recovery of
similarly distributed P. vivax stages from ex vivo cultures.
Comparable zeptomole amounts of PvCRT were measured in the
pRBC of Chesson, AMRU-I, and Indonesia XIX lines (Supple-
mentary Table 14).
Polymorphisms in pvcrt non-coding regions. Figure 3c shows
the schematic of ~4.6 kb DNA sequence from NIH-1993 chro-
mosome 1 carrying MS334 and the pvcrt gene. Sequence com-
parisons (Supplementary Fig. 7) identified multiple TGAAGH
hexanucleotide units interspersed by 10 nucleotide (nt) blocks in
two non-coding stretches of pvcrt: (1) Approximately 0.6 kb
upstream from the start codon, where CQ-S progeny contain 10
TGAAGH motifs and CQ-R progeny contain 15 TGAAGH
motifs in a region that differs by 82 nt; and (2) in intron 9, where
CQ-S progeny contain 17 TGAAGH and CQ-R progeny contain
14 TGAAGH motifs in a region that differs by 60 nt. Interest-
ingly, no analogous introns with TGAAGH motifs occur in the
crt genes of other major Plasmodia clades, including those of P.
falciparum and P. knowlesi; and P. vivax transcripts containing
intron 9 sequences have been reported with a predicted early stop
codon after the repeats31. Although there is currently no
knowledge regarding their role in Plasmodium, TGAAGH motifs
are involved in gene transcription regulation of Arabidopsis,
including cis-acting regulatory elements or CAREs32, intron-
mediated enhancers33, and splicing enhancer motifs34 (Supple-
mentary Table 15). Further evaluation of these and other possible
regulatory elements of gene transcription activity in P. vivax will
require experimental breakthroughs in culture and genetic
manipulation.
Discussion
The P. vivax cross presented in this work links a CQR phenotype
to a 76 kb region of chromosome 1 and greater expression of
pvcrt, an ortholog of the P. falciparum CQR transporter gene.
These results may help to explain evidence of selective pressure in
the 5’UTR and intronic regions of pvcrt in previous studies35–37,
including occurrences in the top 1% of genes with intronic
mutations, although others found no association between the
pvcrt genomic region and P. vivax CQR9,38. Our evidence for
upregulated pvcrt transcription is also consistent with some
findings from patients with CQ-R vivax malaria13,14. However,
such upregulation was not observed in ex vivo assays of patient
samples15. To the extent that greater expression may reverse in
the absence of drug pressure or not maintain well under
laboratory conditions, pvcrt upregulation may be difficult to
detect in ex vivo studies. We also note that determinants in
addition to pvcrt may be involved in P. vivax CQR, or that strains
Table 1 P. vivax genes in the 76 kb region of chromosome 1 selected by chloroquine in mixed populations of NIH-1993 S × R
progeny
Gene ID Location in chromosome 1 (P. vivax Salvador-I) Product description
PVX_087955 313,584–316,927 (−) O1, putative
PVX_087960 317,375–319,103 (−) Inner membrane complex protein 1d, putative
PVX_087970 324,282–326,945 (+) Heat shock protein 110, putative
PVX_087980 330,260–334,540 (+) Chloroquine resistance transporter, putative (pvcrt)
PVX_087985 337,343–340,573 (+) Chloroquine resistance associated protein Cg1, putative
PVX_087990 341,247–342,248 (−) Glutaredoxin domain containing protein
PVX_087995 342,633–349,964 (−) Chloroquine resistance associated protein Cg2, putative
PVX_088000 350,982–355,492 (−) Chloroquine resistance associated protein Cg7, putative
PVX_088005 356,035–356,651 (+) Hypothetical protein, conserved
PVX_088007 357,334–361,250 (−) rRNA/tRNA ribonuclease MRP/P subunit, putative
PVX_088010 362,843–365,107 (−) PST-A protein
PVX_088015 366,877–368,031 (−) Lysophospholipase, putative
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of P. vivax with higher levels of resistance may carry mutations
not present in the NIH-1993-R × S parasites.
A fortuitous aspect of our study was the crossing of two dis-
tinct subpopulations from the NIH-1993 line, of which one was
enriched by sub-therapeutic CQ treatment in the chimpanzee. P.
vivax infections are commonly multiclonal39,40, helping to
explain why NIH-1993-S and NIH-1993-R are closely related to
Sal-I in their genotypes, yet are distinct from each other and from
Sal-I by markers including CSP types, pvdhfr-ts mutations, and
microsatellites of pvcrt. Passages of Sal-I and NIH-1993 through
different host systems, and pressures, such as drug exposure,
would have caused the prevalence of various parasite sub-
populations to change over time. Intriguingly, without CQ pres-
sure, NIH-1993-R type parasites seem to have been less favored
than NIH-1993-S in the monkey infections of our study. We
speculate that the genetic changes P. vivax parasites need to
survive CQ reduce their fitness relative to CQ-S parasites in the
absence of drug pressure, a hypothesis that might help to explain
the slow rise and spread of CQ-R P. vivax relative to P. falciparum
in malaria-endemic regions.
The evidence for pvcrt upregulation in CQ-R P. vivax, as well
as previously demonstrated effects of PvCRT in heterologous
systems11,12 raise intriguing questions about the native function
of this transporter and its role in drug resistance. Why is PvCRT
able to transport CQ, whereas wild-type PfCRT in P. falciparum
can do so only when it harbors specific amino acid mutations12?
How might these various observations relate to findings of
different stage-specific drug responses of P. vivax and P.
falciparum31,41,42 or to possible effects on resistance from post
transcriptional modifications of the protein43? How do PvCRT
and PfCRT differ in their molecular functions? In view of these
questions, it is interesting to consider a proposed model in which
the mutations of P. falciparum CQR might convert the carrier
function of PfCRT from an exchange-only activity to a net
transport function for the drug44. In the case of PvCRT, net
transport of CQ may already be an inherent directional property
of the transporter. Structural explanations for the different
properties of PfCRT and PvCRT will have broad implications for
our understanding of the CRT family of carriers, the natural
functions of which remain unknown.
Methods
Plasmodium lines. P. vivax NIH-1993 was obtained from NIH archive cryopre-
served samples from Aotus T308, May 1993. The following strains were obtained
from the Biodefense and Emerging Infections Research Resources Repository (BEI
resources, NIAID, NIH, Manassas, VA, USA): P. vivax AMRU-I (catalog number
MRA-372), Indonesia-XIX (catalog number MRA-378), and Chesson (catalog
number MRA-383), contributed by William E. Collins. Parasite line NIH-1993 line
was initially identified in NIH stocks as the CQ-S Salvador-I strain. However,
comparisons to the nuclear chromosome sequences and the mitochondrion gen-
ome of Salvador-I [https://www.ncbi.nlm.nih.gov/nuccore/AY598140.1] showed
polymorphisms that distinguish NIH-1993 and Salvador-I, including three dihy-
drofolate reductase mutations at codon positions 57, 99, and 173 (Supplementary
Table 1).
P. vivax nonhuman primate infections. All animal procedures were performed in
compliance with the National Institutes of Health (NIH) Guidelines under pro-
tocols approved by the National Institute of Allergy and Infectious Diseases Animal
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Fig. 3 Evidence for increased pvcrt transcription in CQ-selected P. vivax. a Levels of pvcrt transcription in mixed progeny from the NIH-1993 S × R cross
before and after CQ treatment in five different Aotus or Saimiri monkeys. Black bars indicate pvcrt transcription levels in the CQ-selected progeny,
normalized to the transcription levels in unselected progeny before CQ treatment (gray bars). Transcription levels were calculated relative to those of the
pvseryl-tRNA synthetase ‘housekeeping’ gene by the 2−ΔΔcT method63. PCR determinations for the calculations were performed in duplicate. Thawed
samples of cryopreserved parasitized erythrocytes were used in all experiments, thereby enriching for ring-stage parasites and reducing potential variations
from older parasite stages. A single post-CQ selection sample was collected from Aotus WR454 and from Saimiri 4919; post-CQ treatment samples were
collected on two different days from each of Aotus 86121, Aotus 85986, and Saimiri 5081. Error bars indicate standard deviations from two technical
replicates shown as white triangles in the graph. b Estimated PvCRT protein concentration per parasitized erythrocytes in monkey blood samples infected
with from NIH-1993 SR unselected (gray) and selected (black) progeny. Points for each strain are the estimated levels, and lines represent geometric
means and the associated 95% confidence intervals from 5 or 6 biologically independent samples. zMol zeptomole. c Schematic of the P. vivax
chromosome 1 segment containing the exons, introns, and untranslated flanking regions of pvcrt. Multiple repeats of the TGAAGH motif occur in MS334
and intron 9. F9 indicates the region from exon 9 where the sequence of forward primer used to perform qRT-PCR is located and R11 the region where the
sequence of the reverse primer is located (see the “Methods” section). The asterisk indicates where codons of the peptide used for MRM analysis are
located (exon 13)
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Care and Use Committees (NIAID ACUC) and from Bioqual Inc. (Rockville, MD,
USA). Aotus nancymaae, Saimiri boliviensis, and Pan troglodytes (hereafter referred
to as Aotus, Saimiri, and chimpanzee) were obtained from NIH approved sources
and housed in compliance with the Animal Welfare Act and the Guide for the Care
and Use of Laboratory Animals45. Cryopreserved or fresh NHP-parasitized blood
samples (between 0.5 and 1.5 mL) were thawed and washed in sterile RPMI 1640
(KD Medical, Columbia, MD, USA) and inoculated intravenously (IV) into ani-
mals anesthetized with 10 mg/kg ketamine. Thin and thick blood smears from
animals inoculated with P. vivax were checked weekly until parasites were detected
microscopically (in counts of ~10,000 erythrocytes from a thin blood smear, fixed
with methanol and stained with 20% Giemsa), then checked daily. For blood
smears and hematocrit measures, between 0.01 and 0.05 mL blood were obtained
from the saphenous vein or by ear prick; larger blood draws for parasite cryo-
preservation, DNA/RNA extraction, and drug plasma level measurements were
obtained from the femoral vein of anesthetized animals.
Treatment regimens of 3 days of 2.5, 5.0, or 10.0 mg/kg/day CQ (delivered via
gavage) were administered to monkeys that achieved a minimum parasitemia of
0.2%. A blood sample of ~1.5 mL for parasite cryopreservation, DNA, and plasma
analysis was collected prior to the first dose of treatment. Another 0.3–0.5 mL
blood sample was collected for CQ plasma measurement on the 4th day after
completion of treatment. Parasitemias were monitored daily for 7 days from the
beginning of CQ treatment or until parasitemia cleared and then were checked for
parasite recrudescence at least weekly until 62 days after treatment. Blood samples
from the recrudescences were collected for cryopreservation and other analyses
indicated in the text.
Definitive cure of New World monkeys infected by blood stage parasite
inoculation was achieved by mefloquine HCl (single 25 mg dose) or by three daily
administrations of 25 mg atovaquone/10 mg proguanil HCl (Malarone, pediatric
weight-adjusted dose). Cure of the chimpanzee infection from the blood-stage
inoculation was by three daily administrations of 187.5 mg atovaquone/75 mg
proguanil HCl (Malarone, pediatric weight-adjusted dose); cure of the infection
from the sporozoite inoculation in the more grown chimpanzee was by three daily
administrations of 250 mg atovaquone/100 mg proguanil HCl (Malarone, adult
strength), plus primaquine base to eliminate liver stage hypnozoites (3 days of 34
mg/day)46. The antimalarials were delivered orally from preparations of crushed
tablets mixed in Ensure liquid. Clearance of any residual infection was confirmed
by a high sensitivity PCR test47.
P. vivax mosquito infections and sporozoite inoculations. For production of P.
vivax sporozoites, 3–5-day-old female A. stephensi, A. freeborni, A. dirus, and A.
gambiae mosquitoes were raised in the LMVR/NIAID and at Sanaria Inc. Indivi-
dual secure pint or gallon containers were populated with up to 100 and 500 female
mosquitoes, respectively. After starvation of 24 h, the mosquitoes were fed for
10–20 min via artificial membrane feeding or directly onto the shaved abdomen of
the anesthetized chimpanzee. The fed mosquitoes were maintained with 5% corn
syrup and water at 26 °C for up to 18 days in a secure insectary. Randomly selected
mosquitoes were dissected 6–9 days post-feeding and examined for oocysts in the
midgut; additional mosquitoes were randomly selected and dissected after
12–14 days to check for sporozoites in the salivary glands. To assess oocyst pre-
sence and numbers, midguts from 10 to 15 dissected mosquitoes/container were
stained with 0.5% mercurochrome for 10 min then observed with a microscope
using a ×20 or ×40 objective lens. Stained oocysts were isolated from the midgut
using #5 tweezers (Sigma, St. Louis, MO, USA) and a 23-gauge needle attached to a
syringe containing phosphate-buffered saline (PBS; 10 mM Na2HPO4, 2 mM
KH2PO4, 137 mM NaCl, 2.7 mM KCl, pH 7.4). Individual pieces of mosquito
midguts containing single oocysts were transferred to 50 µL of a homogenization
buffer containing 80 mM EDTA, 100 mM Tris pH 8.0, and 160 mM sucrose48, and
frozen in 1.5 mL tubes at −20 °C until DNA extraction. Sporozoites were isolated,
purified, cryopreserved, and confirmed to be infective in hepatocyte invasion
assays18. For inoculation of the chimpanzee with progeny of the cross, cryopre-
served sporozoites were rapidly thawed in a 0.6% albumin saline solution sus-
pension for 30 s in a circulating water bath at 37 °C and inoculated intravenously
within 15–30 min of thawing.
Immunofluorescence antibody assay (IFA) of sporozoites. Purified sporozoites
were suspended in PBS containing 2% bovine serum albumin (BSA, Life Tech-
nologies, Carlsbad, CA, USA). Twenty microliters of this suspension containing
~2000 sporozoites were spotted into individual wells of an immunofluorescence
slide (Erie Scientific, Ramsey, MN, USA). The slide was air-dried at room tem-
perature for 24 h before IFA of the P. vivax circumsporozoite protein (PvCSP) with
monoclonal antibody (MAb) VK210, which recognizes the PvCSP common repeat
GDRADGQPA (Mab NVS3 Cat#WRAIR, gift from CDC Dr. Robert Wirtz) and
MAb VK247, which recognizes the PvCSP variant repeat ANGAGNQPG
(Cat#MRA-1028K, BEI Resources, NIAID, NIH, Manassas, VA). Twenty micro-
liters of MAb VK210 (used at 0.1 μg/mL, which is a 1:10,000 dilution of the stock of
1 mg/mL) was added to each slide well containing air-dried sporozoites and
incubated at 37 °C in a humid chamber for 30 min. After three washes of the slide
with PBS (5 min each), 20 μL of Alexa Fluor 488 Goat anti-mouse IgG (Product #
A28175, Thermo Fisher, used at 1 µg/mL in phosphate-buffered saline containing
0.2% BSA) were added to each well and incubated for 30 min at 37 °C in a humid
chamber. After three washes again with PBS, 20 μL of PvCSP VK247 MAb at 0.1
μg/mL were added to each well. Slides were then incubated at 37 °C in a humid
chamber for 30 min, washed three times with PBS, and processed with 20 μL of
Alexa Fluor 568 Goat anti-mouse IgG (Product # A-11004, Thermo Fisher, used at
1 µg/mL) as described above for Alexa Fluor 488. Cover slips were applied to the
slides using Vectashield mounting medium (Vector Laboratories, Inc., CA, USA).
Examination and imaging was performed in an Olympus BX-40 fluorescent
microscope equipped with FITC and TxRed filters.
Mature blood-stage parasite isolation and DNA extraction. Magnetic LS
separation columns (MACS®, Miltenyi Biotec, Sunnyvale, CA, USA) were used to
isolate mature blood-stage parasites from uninfected erythrocytes, host white blood
cells, and platelets49. NHP blood samples were centrifuged at 2500 rpm for 5 min to
separate and remove serum. Blood cells were used to make a 0.5–1.5% hematocrit
solution in RPMI 1640 (KD Medical). The magnetically purified parasites were
eluted with 3 mL RPMI 1640, split into two 1.5 mL tubes. After centrifugation at
2500 rpm for 5 min, ~90% of the volume of each tube was discarded and the pellet
was frozen at −20 °C. DNA from these cells was obtained by standard
phenol–chloroform methods50, suspended in 50 µL of 10 mM Tris–0.1 mM EDTA
pH 8.0, and frozen. These same methods were used to extract DNA from oocysts
and sporozoites. To increase DNA template for microsatellite analysis or genome
sequencing, whole genome amplification (WGA) was performed with 2–5 µL of
samples of extracted DNA using the Repli-G midi kit (Qiagen, Germantown, MD,
USA)51.
RNA isolation and cDNA synthesis. Cryopreserved samples of parasitized blood
were thawed by standard methods, which favor the recovery of ring-stage infected
erythrocytes52. RNA was extracted by phenol–chloroform methods50 after solu-
bilization of the thawed cells in Trizol (Sigma). Samples of 1–3 µg total RNA were
treated with Amplification Grade Deoxyribonuclease I as recommended by the
manufacturer (Life Technologies); cDNA was synthesized with the SuperScript III
First-Strand Synthesis Super Mix kit using random primers (Life Technologies).
P. vivax microsatellite analysis. All genomic DNA samples were genotyped and
analyzed blindly. A list containing the sequence of all oligonucleotide primers used
in this study is presented at the end of the Methods section. Thirty-five poly-
morphic microsatellite markers that distinguish the NIH-1993-S, NIH-1993-R, and
AMRU-I parasites were identified from a screen of 232 previously reported
microsatellites sequences distributed over the 14 P. vivax chromosomes53–56
(Supplementary Table 9). Because only 35 markers of the 232 tested differed
between NIH-1993 S and R, two additional microsatellite markers were identified
to carry polymorphic regions in pvcrt intron 9 (marker In9pvcrt) on chromosome
1, and in a sequence nearby pvmdr-1 (MSnMDR) on chromosome 10. Between 20
and 100 ng of WGA DNA were amplified using Platinum PCR SuperMix High
Fidelity polymerase (Life Technologies) and a 6-fluorescein amidite-modified
fluorescently labeled oligonucleotide in the reverse primer of each pair (0.5 µM).
Amplified PCR products were obtained after 42 cycles of 20 s at 94 °C, 10 s at 52 °C,
10 s at 47 °C, and 30 s at 60 °C. The PCR products were diluted 100–1000-fold and
evaluated for size differences and relative intensities using an ABI 3730xl DNA
Analyzer (SeqGen, Torrance, CA, USA). The CQ selection effect E-value of each
marker was calculated as the ‘ratio of ratios’ of signals from the two inherited
parental polymorphisms in LGS progeny pairs after and before CQ treatment:
E ¼ markerNIH1993Rafter=markerNIH1993Safter
 
= markerNIH1993Rbefore=markerNIH1993Sbefore
 
Targeted Illumina sequencing. DNA of MACS-purified parasites from the 10
LGS pairs pre-CQ and post-CQ treatment was whole genome-amplified as
described above. Sample-indexed shotgun Illumina TruSeq libraries were generated
from WGA DNA by recommended kit conditions (Illumina, San Diego, CA, USA).
Of the 10 LGS pairs, six (from Aotus 85922, 85986, 85850, WR454, 85823, and
Saimiri 4919) were fully analyzed. Results from four LGS sample pairs could not be
included because recovered DNA was not sufficient from the PCR-positive-only
recrudescences in the monkeys (Aotus 86121, 85891, Saimiri 5081, and 5076;
Supplementary Fig. 4). Chromosomes 1 and 5 sheared fragments were captured
using custom SureSelect RNA baits with 3 × tiling (Agilent Technologies, Santa
Clara, CA, USA) and were sequenced on an Illumina HiSeq2000.
Reads were aligned to the P. vivax Salvador I reference assembly genome
(version 3) using bwa-mem with default settings. Aligned reads were deduplicated
with Picard Tools MarkDuplicates and then had mate information fixed with
Picard Tools FixMateInformation. Finally, the aligned reads underwent local
realignment of entropic regions using Genome Analysis Toolkit (GATK)
IndelRealigner57–60. Read coverage and statistics were calculated with SAMtools
flagstat61 and custom R scripts.
Variant discovery was performed using samtools mpileups with flags for max-
depth of 10,000 bases, minimum base quality of 20, and a minimum mapping
quality of 10. The output from mpileups was then passed to bcftools multiallelic-
caller. Loci were filtered using bcftools filter for an INFO field mapping quality of
<55 and if a SNP occurred within five-base pairs of an INDEL. Loci were also
excluded if they were not within the core region defined by Pearson, Amato9 or if
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they were annotated in the P. vivax Salvador I GFF (version 3) as members of the
msp, Pvfam-c, VIR, SERA, or STP family21. In addition, variants were subsetted to
biallelic SNPs. These were filtered further and excluded if the within-sample allele
depth was <10 or if the phred-scaled strand bias p-value was >10. After these filters
were applied, variants were excluded across all samples if more than 2/12 samples
had missing information or if the range of within-sample allele frequencies across
all samples was <5% suggestive of genotyping error.
Quantitative real time PCR (qRT-PCR) analysis of pvcrt. All qRT-PCR analyses
were performed using the Rotor-Gene SYBR Green PCR Kit according to manu-
facturer’s instructions (Qiagen). For each reaction a total of 30 ng cDNA and 1 µM
of each primer were mixed with the Rotor-Gene PCR SYBR Green mix and ana-
lyzed in the Rotor-Gene Q over 35 cycles, each consisting of two steps: 10 s at 96 °C
and 30 s at 60 °C. For quantitative transcription analysis, the threshold cycle value
(Ct) was used to estimate the ΔCt of each sample relative to that of the house
keeping gene seryl tRNA synthetase (PVX_123480, an ortholog of P. falciparum
PF3D7_1216000);62 calculated 2-ΔΔCt values63 provided comparative measure-
ments of pvcrt transcript levels in samples from each LGS pair before and after CQ
selection. Expected PCR products from cDNA were 151 bp for pvcrt using oligo-
nucleotide primers pvcrt-RT-Fwd and pvcrt-RT-Rev from exon 9 to 11, and 116 bp
for pvseryl-tRNA-synthetase, using primers pvSerylT-RNA-Fwd and pvSerylT-
RNA-Rev. A list containing the sequences of oligonucleotide primers used in this
study is presented in Supplementary Table 16.
Quantification of PvCRT protein levels. We performed liquid chromatography
multiple reaction monitoring (LC–MRM) using a triple quadrupole (QQQ) mass
spectrometer to measure the abundance of PvCRT in infected NHP erythrocytes
infected with various strains of P. vivax. For this purpose, we identified candidate
tryptic peptides likely to be of high quality, and which confirmed with the mini-
mum general rules for the peptide’s use in LC–MRM: no fewer than eight amino
acids; no known post-translational modifications; no missed cleavages; and no
predilection to artifactual modifications (empirically determined by MS/MS ana-
lyses). Before use of the limited P. vivax samples, we performed experiments with
the orthologous PfCRT peptides from P. falciparum cultures, which provided larger
amounts of infected red cells and samples of greater scale. An orthologous peptide
of PvCRT IGNIILEK (the PfCRT peptide VGNIILER; 85% sequence identity) met
the quality thresholds for confident identifications and was readily identified in
replicate LC–MS/MS runs. Another PfCRT peptide identified from our in silico
predictions could also be observed, but it was less abundant, supporting VGNIILER
as the preferred choice for PfCRT quantification in samples with low parasite
densities. By procedures described below, testing of samples from P. vivax-infected
Saimiri confirmed that the orthologous PvCRT peptide, IGNIILEK, was readily
detected at low parasitemias and provided the requisite high-quality spectrum for
PvCRT quantification.
To reduce the number of uninfected cells, which contribute to hemoglobin
contamination, and enrich parasite blood stages with a developed food vacuole,
where PvCRT is expected to be expressed, each blood sample was passed through a
MACS column. The number of parasites to be purified was estimated based on the
percentage parasitemia of hemozoin-containing parasites (trophozoites, schizonts,
and gametocytes), and number of cells that passed through the column was
counted using a cell counter (Nexcelom Biosciences, MD, USA). The eluate was
treated with saponin washed with SigmaFastTM protease inhibitor (Sigma) and
snap frozen. After thawing, samples were suspended and boiled at 95 °C in variable
volumes of SDS and dithiothreitol buffer (4% (w/v) SDS, 0.1 M Tris/HCl pH 7.6,
0.1 M DTT) as listed in Supplementary Table 14. Part of the extracted protein
supernatant was digested using the Filter Aided Sample Prep (FASP)
procedure64,65 (volumes listed in Supplementary Table 14) and HPLC was
performed to desalt the FASP-digests. Prior to LC–MRM analysis, the sample load
was estimated and normalized by comparison with soluble samples whose
concentrations, as determined by bicinchoninic acid (BCA) assay, were known.
This approach allowed us to estimate the concentration of the FASP-digestion
peptide products at the HPLC desalting step by using the integrated area at 214 nm
and standardizing to the known concentration of total digested peptides.
We obtained MRM determinations that included three transitions for the
selected PvCRT IGNIILEK peptide (Supplementary Table 12); the choice of three
pair-transitions detected a 6 Da difference between an internal 13C heavy-labeled
lysine standard peptide and the digested PvCRT peptide product ions. Desalted
peptide digests (~30 µg) were spiked with 100 fmol heavy labeled lysine (K) internal
standard peptide IGNILEK(13C6). An Agilent 1290 Infinity UHPLC system was
used to inject 17 µL of the desalted peptide digests/internal standard mix onto a
reversed phase analytical column (150 mm × 2.1 mm i.d., Agilent Poroshell 120
EC-C18, 2.7 µm particle size) that was maintained at a temperature of 40 °C.
Elution of peptides from the analytical column was performed using a gradient
starting at 97% A (A: 99.9% water, 0.1% formic acid (FA)) at 0.5 mL/min. The
mobile phase was 3–10% B (B: 90% acetonitrile (ACN), 9.9% water, 0.1% FA) for 3
min, 10–45% B for 9 min, 45–99% for 1 min, and maintained at 99% B for 3 min,
followed by re-equilibration of the column with 3% B for 4 min. An Agilent 6490
QQQ LC/MS with iFunnel technology, controlled by Agilent’s MassHunter
Workstation software (version B.06.00), was used for all LC–MRM sample
analyses. All acquisition methods used the following parameters: 3000 V capillary
voltage and a 1500 V nozzle voltage, a sheath gas flow of 11 L/min (nitrogen) at a
temperature of 250 °C, a drying gas flow of 14 L/min at a temperature of 200 °C,
nebulizer gas flow at 20 psi, and Q1 and Q3 set to unit resolution (0.7 FWHM).
MRM acquisition methods were composed of three ion pairs during the acquisition
of high-signal producing interference-free transitions and LC method
development. A default 380 V fragmenting voltage and 5 V cell accelerator
potential were used for all MRM ion pairs, and the dynamic MRM option was used
for all data acquisition with a target cycle time of 500 ms. The collision energy for
both the heavy labeled and light peptides was set at 20.0 V.
Statistical analysis. Analysis of Fig. 2a: In Fig. 2a, if there was no change in the
prevalence of the NIH-1993-R and NIH-1993-S between the before and after CQ
treatment, then we would expect that the E value for each monkey and marker
would be equally likely to be >1 or <1. We test this null hypothesis using a Monte
Carlo version of a within-cluster resampling test66. To motivate this, first note that
there are 37 polymorphic microsatellite markers measured on 14 chromosomes.
Because E values are likely to be correlated within chromosomes, we cannot assume
the 37 markers are independent, instead we assume independence between markers
on different chromosomes. Under this assumption, we can randomly select one
marker from each chromosome and test for an effect on those 14 markers. The p-
value is the simulated probability of observing equal or more extreme data (for
Fig. 2a, this is the probability that 1 or more out of the 14 chromosomes will have
all 10 E values either > 1 or < 1). The resulting simulated two-sided p-value (using
1e+ 5 replications) is p1(chrom)= 0.02624. This p-value applies to any random
selection of 14 markers (one from each chromosome) for the data in Fig. 2a, since
the only markers with all 10 E values the same are both on chromosome 1. Because
the p-value could apply to any random selection, the p-value can be interpreted as a
within-cluster resampling test of the entire figure66.
Analysis of Fig. 2b and Supplementary Fig. 6: To detect selection valleys, we
calculated within-sample allele frequencies (WSAF) from the filtered SNP-sites to
produce a pre-CQ and post-CQ treatment WSAF for each monkey. Resulting
WSAF were then smoothed with respect to chromosome and position by using a
40-SNP running median sliding window with the “median” endrule and the
Turlach algorithm from the R-statistical software stats package [https://www.R-
project.org]. As a result of this smoothing algorithm, samples with missing WSAF
were dropped from the sliding window, the first 20 SNPs on each chromosome
were burned-in, and the last sliding-window on each chromosomes was a subset of
the 40-SNPs, as chromosomes are uneven. Correlations due to linkage
disequilibrium were not taken into account, as we were searching for signs of
linkage-disequilibrium with the linkage-group selection method19.
In order to aggregate the smoothed-WSAF, we performed 10,000 bootstrap
iterations (selecting six monkeys with paired pre-CQ and post-CQ treatment
smoothed-WSAF with replacement) and calculated the median of the smoothed-
WSAF at each of the loci for each iteration with respect to treatment status. From
these bootstrapped results, we then performed a log-base-2 fold transformation
between the pre-CQ and post-CQ treatment smoothed-WSAF. As a result of this
transformation, decreases in smoothed-WSAF from pre-CQ to post-CQ treatment
will be expressed as a negative value, while the null value of zero will indicate no
change in in smoothed-WSAF with respect to treatment status. To account for
allele frequencies of 0% we added a 1e−3 tolerance to all log-base-2 calculations.
This tolerance factor is the lower bound of the confidence intervals. The median
and the 95% confidence interval from the bootstrapped results are presented in
Fig. 2b and Supplementary Fig. 6. Given that there were so few samples, the 95%
confidence intervals are rough approximations. Further, there was no adjustment
for multiplicity. Nevertheless, the intervals may be treated as descriptive statistics,
so intervals that do not cross the null value of 0 to highlight loci where the
smoothed-WSAF decreased between pre-CQ and post-CQ treatments. These
regions likely indicate linkage group selection valleys.
Analysis of Fig. 3a: The panel shows data from five monkeys: two measurements
(from unselected and selected progeny) are provided from each of two monkeys,
and three measurements (one from unselected and two from selected progeny)
from each of three monkeys. If each monkey had been measured only once after
CQ treatment, then we could take the log of the fold change for all five monkeys
and perform a t-test. Taking the mean of the log(fold-change) and exponentiating
gives the geometric mean of the fold-change, and exponentiating the confidence
limits gives a confidence interval on the fold-change. Since we repeated after-
treatment measurements on three monkeys, we use within-cluster resampling to
perform the analysis66. Similar to the t-test method described above, we work on
the log-transformed responses and back-transform the results. Instead of using a
normal distribution for inferences, we use the t distribution with four degrees of
freedom, so that if there had been no repeated measurements, the results would be
equivalent to the previously mentioned t-test methods.
Analysis of Fig. 3b: Confidence intervals used log-transformed values and either
a one-sample t-test (for within group confidence intervals) or Welch’s two-sample
t-test (for comparisons between groups). Resulting CIs are exponentiated to return
to the original scale (one-sample CIs) or to give CIs in terms of ratios of geometric
means (two-sample CIs).
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
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Data availability
Genome sequencing data from the NIH1993-S parent are deposited in the NCBI Short
Read Archive under accession number SRR2148599. Targeted Illumina sequencing data
of NIH-1993 S × R progeny LGS sample pairs are deposited under accession numbers
SRR2148595, SRR2148596, SRR2148597, SRR2148598, SRR2148600, SRR2148601,
SRR2148602, SRR2148603, SRR2148604, SRR2148605, SRR2148606, and SRR2148607.
The data underlying Fig. 1a, Supplementary Fig. 2a, and Supplementary Table 5 are
provided as a Mendeley dataset [https://data.mendeley.com/], Sa, Juliana (2019), “Pv-X
raw data”, https://doi.org/10.17632/4455hbjb9g.1.
Code availability
The analyses for Figs. 2a, 3a, b were performed using the R computer language and the
Sweave system of Rstudio [http://www.rstudio.com]. The files are provided as
Supplementary Software: Analyses_for_Figures_2a_3a_3b.Rnw (Sweave file) and the
associated PDF file. R code employed for the analyses is embedded in the.Rnw file to
create the.pdf file.
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